Revenio Group Corporation: Paying Revenio Group Corporation Board members' fees in the form of shares held by the company

Revenio Group Corporation, Stock Exchange Release, May 27, 2016 at 14:00

PAYING REVENIO GROUP CORPORATION BOARD MEMBERS' FEES IN THE FORM OF SHARES HELD BY THE COMPANY

With reference to Board meeting fees, Revenio Group Corporation's AGM decided on 15th of March 2016 that 40% of the fee paid to a Board member should be paid in company shares. According to the decisions taken at the AGM and by the Board, Revenio Group Corporation has transferred to Board members a total of 2,455 shares as a part of their Board fees as follows:

A total of 819 shares were transferred to chairman of the Board Pekka Tammela. As a result of the transfer, his holdings in Revenio Group Corporation and other instruments issued by Revenio Group Corporation amount to 26,888 shares.

A total of 409 shares were transferred to Board member Ari Kohonen. As a result of the transfer, his and his nearparty holdings in Revenio Group Corporation and other instruments amount to 342,269 shares.

A total of 409 shares were transferred to Board member Pekka Rönkä. As a result of the transfer, his holdings in Revenio Group Corporation and other instruments issued by Revenio Group Corporation amount to 1,210 shares.

A total of 409 shares were transferred to Board member Kyösti Kakkonen. As a result of the transfer, his and his nearparty holdings in Revenio Group Corporation and other instruments issued by Revenio Group Corporation amount to 592,719 shares.

A total of 409 shares were transferred to Board member Ann-Christine Sundell. As a result of the transfer, his holdings in Revenio Group Corporation and other instruments issued by Revenio Group Corporation amount to 809 shares.

As a result of these transfers, the share-based Board member fees have been completely settled for the year 2016. Revenio Group Corporation now holds a total of 4,959 of its own shares.

Revenio Group Corporation
Olli-Pekka Salovaara
President and CEO

For additional information:
President & CEO Olli-Pekka Salovaara, gsm +358 (0)40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims at developing even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2015, the Revenio Group's net sales totaled MEUR 20.3, with its operating margin for continuing operations standing at 28.4%. Revenio Group Corporation is listed on Nasdaq Helsinki.